Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 3/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 2/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Monoacetylcystine SCHEMBL20816346 | 0.94 | ITGB1 (0.48) | ITGB1ITGA4MAPTKDM4ETHRB | |
| SCHEMBL20839967 | 0.90 | ITGB1 (0.42) | ITGB1ITGA4MAPTKDM4ETHRB | |
| SCHEMBL2947907 | 0.88 | ITGB1 (0.46) | ITGB1ITGA4MAPTKDM4ETHRB | |
| SCHEMBL2947915 | 0.88 | ITGB1 (0.46) | ITGB1ITGA4MAPTKDM4ETHRB | |
| SCHEMBL2947906 | 0.88 | ITGB1 (0.46) | ITGB1ITGA4MAPTKDM4ETHRB | |
| SCHEMBL24359843 | 0.87 | ITGB1 (0.57) | ITGB1ITGA4MAPTKDM4ETHRB | |
| N-Monoacetylcystine SCHEMBL20816351 | 0.87 | MAPT (0.48) | ITGB1ITGA4MAPTKDM4ETHRB | |
| N-Monoacetylcystine SCHEMBL468826 | 0.87 | MAPT (0.48) | ITGB1ITGA4MAPTKDM4ETHRB | |
| N-Monoacetylcystine SCHEMBL29438781 | 0.87 | MAPT (0.48) | ITGB1ITGA4MAPTKDM4ETHRB | |
| N-Monoacetylcystine SCHEMBL111494 | 0.87 | MAPT (0.48) | ITGB1ITGA4MAPTKDM4ETHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3028696-B1 | AGENT FOR ALLEVIATING SIDE EFFECTS IN CANCER CHEMOTHERAPY | AJINOMOTO KK (JP) | 2021-01-27 | — | — | EP | disclosed |
| US-10786471-B2 | Methods and products related to glutaminase inhibitors | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-09-29 | — | — | US | disclosed |
| WO-2018145109-A1 | METHODS AND PRODUCTS RELATED TO GLUTAMINASE INHIBITORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-08-09 | — | — | WO | disclosed |
| US-20180221321-A1 | METHODS AND PRODUCTS RELATED TO GLUTAMINASE INHIBITORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-08-09 | — | — | US | disclosed |
| EP-3028696-A1 | AGENT FOR ALLEVIATING SIDE EFFECTS IN CANCER CHEMOTHERAPY | Ajinomoto Co., Inc. (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-20160143871-A1 | AGENT FOR ALLEVIATING SIDE EFFECTS IN CANCER CHEMOTHERAPY | AJINOMOTO CO., INC. (JP) | 2016-05-26 | — | — | US | disclosed |
| CN-105392478-A | Agent for reducing side effects in cancer chemotherapy | AJINOMOTO KK | 2016-03-09 | — | — | CN | disclosed |
| US-7767714-B2 | Method of preventing infectious diseases | AJINOMOTO CO., INC. (JP) | 2010-08-03 | — | — | US | disclosed |
| EP-1486208-B1 | USE OF A NOVEL PREVENTIVE FOR INFECTIONS | AJINOMOTO KK (JP) | 2006-09-27 | — | — | EP | disclosed |
| US-20050090511-A1 | Novel method of preventing infectious diseases | AJINOMOTO CO., INC. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486208-A1 | NOVEL PREVENTIVE FOR INFECTIONS | Ajinomoto Co., Inc. (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-5780508-A | IMMUNOSTIMULANTS N,N'-DIACETYL-L-CYSTINE | ASTRA AKTIEBOLAG (SE) | 1998-07-14 | — | — | US | disclosed |
| WO-1997046229-A1 | NEW USE OF DERIVATIVES OF CYSTINE | ASTRA AKTIEBOLAG (SE) | 1997-12-11 | — | — | WO | disclosed |
| EP-0532595-B1 | THE PHARMACOLOGICAL USE OF CERTAIN CYSTINE DERIVATIVES | ASTRA AB (SE) | 1996-10-30 | — | — | EP | disclosed |
| EP-0727207-A1 | The pharmacological use of certain cystine derivatives | Astra Aktiebolag (SE) | 1996-08-21 | — | — | EP | disclosed |
| US-5441976-A | Immunostimulants | AKTIEBOLAGET ASTRA (SE) | 1995-08-15 | — | — | US | disclosed |
| EP-0532595-A1 | THE PHARMACOLOGICAL USE OF CERTAIN CYSTINE DERIVATIVES. | ASTRA AB (SE) | 1993-03-24 | — | — | EP | disclosed |
| WO-1991018594-A1 | THE PHARMACOLOGICAL USE OF CERTAIN CYSTINE DERIVATIVES | AKTIEBOLAGET ASTRA (SE) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221321-A1 | METHODS AND PRODUCTS RELATED TO GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | ITGB1 4163/4885ITGA4 4550/4885MAPT 3652/4885 |
| US-10786471-B2 | Methods and products related to glutaminase inhibitors | GLS, GLS2, GLUL | ITGB1 4163/4885ITGA4 4550/4885MAPT 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.